Sage NMDA Modulator Fails In Alzheimer’s Months After Parkinson’s Disappointment

 
• By Joseph Haas
  
Sage missed on the second of three Phase II studies of dalzanemdor in neurodegenerative disease
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

More from R&D